Alpha Wave Global LP Cuts Stake in Lifecore Biomedical, Inc. $LFCR

Key Points

• Alpha Wave Global LP has reduced its holdings in Lifecore Biomedical, Inc. by 38.0%, now owning 72,260 shares, which represents about 0.2% of its investment portfolio.
• Major shareholder Aron R. English sold 150,419 shares at an average price of $7.12, leading to a 36.28% decrease in their ownership.
• Lifecore Biomedical reported a quarterly revenue of $36.44 million, but missed the EPS consensus estimate, achieving ($0.10) compared to the expected ($0.09).

Alpha Wave Global LP lowered its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 38.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 72,260 shares of the company's stock after selling 44,278 shares during the quarter. Lifecore Biomedical accounts for 0.2% of Alpha Wave Global LP's portfolio, making the stock its 21st biggest position. Alpha Wave Global LP owned 0.20% of Lifecore Biomedical worth $509,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bridgeway Capital Management LLC raised its holdings in shares of Lifecore Biomedical by 2.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 78,800 shares of the company's stock valued at $585,000 after acquiring an additional 1,900 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Lifecore Biomedical by 29.0% during the fourth quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock valued at $99,000 after acquiring an additional 3,012 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Lifecore Biomedical by 3.8% during the first quarter. Bank of New York Mellon Corp now owns 83,663 shares of the company's stock valued at $589,000 after acquiring an additional 3,091 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Lifecore Biomedical by 1,839.7% during the first quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock valued at $25,000 after acquiring an additional 3,385 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in shares of Lifecore Biomedical during the first quarter valued at approximately $26,000. Institutional investors own 83.36% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on LFCR shares. William Blair started coverage on Lifecore Biomedical in a report on Wednesday, May 21st. They set an "outperform" rating for the company. Wall Street Zen upgraded Lifecore Biomedical from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $8.00.

Lifecore Biomedical Stock Up 1.2%

LFCR stock traded up $0.09 during midday trading on Thursday, hitting $7.62. The stock had a trading volume of 75,742 shares, compared to its average volume of 115,480. The firm has a market cap of $285.06 million, a price-to-earnings ratio of -5.82 and a beta of 0.65. The business has a 50-day moving average of $7.65 and a two-hundred day moving average of $6.85. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $8.85. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.84 and a quick ratio of 1.77.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The firm had revenue of $36.44 million during the quarter, compared to analysts' expectations of $35.36 million. Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%. Lifecore Biomedical has set its FY 2026 guidance at EPS. As a group, equities research analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.